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f'or the study of the ~tructure and ful:¢tion relationship of dystrophin, defective inDMD. and for diagnostic purpose~ it is important to dispo~ 
of antibodies a~il~st different par.i of the protein. We have mud.' five different eonstruct~ far the expression of fusion proteins containing parts 
of the four domain~s ot" dy=itrophin. Two different recombinant expre~ion ~'ectors. pATH2 and pEX 1. were u~d, Rabbits were immuni=ed with 
the fusion product.= lind ~veral pol)'clomtl antibodi~ were rai~d, At a later s:a~e, monoclonal ntibodi~ were al~ rai~.d to rome of the fusion 
protein,=, One pol)'¢lonal antibody, named P20 AB. is directed a~tlnst he region ¢overin~ amino acid ~tluenee 1749.,2241~ orthe nu¢leotide ~,¢quence 
~56-6053 of the nlRNA, which corresponds to the major dcletion.prot~e r gion of the DMD ~cne, We show the particular value, ~n~itivity and 
sr.,c¢ifi¢ity of the P2O AB in dystrophin ~nalysis. 
D~,~trophin: pATH2 fusion protein; pEXI fusion protein: Duehcnnc mu~:uhtr d)~trophy: P20 mutation he/spot; Pol)'clenal anti.rum 
1. INTRODUCTION 
Duchenne mu~:ular dystrophy (DMD~ is a progres. 
sire lethal disorder, which affcct=i 1:3500 ntwborn boys. 
The gene involved in DMD encodes a 427 kDa protein 
named dystrophin [1] and is the largest gone (2300 kb) 
known so far [2], Dy~trophin is present in low abun- 
dance (0,01% of  total skeletal muscle protein) and is 
localized at the cytoplasmatic face of the sarcolemma 
[3-5], In Duchenne patients dystrophin is absent from 
most (>98%) or all muscle cells. In muscle of Becket 
(BMD) patients dystrophin is present with altered size 
and/or at different levels [6], In order to study the struc- 
ture and function ofdystrophin and carry out diagnos- 
tic studies on muscle of DMD/BMD patients and pa- 
tients with related muscular disorders, antibodies 
against dystrophin are required, We therefore con- 
structed fusion protein~ with which we raised antibodies 
against various domains of dystrophin. 
Dystrophin consists of four domains (Fig. 1): an N- 
terminal domain (A), a central rod-shaped triple-helical 
domain counting 24 repeat unit-., of about 109 amino 
acids (B). a cysteine.rich domain (C) and a C-terminal 
domain (D) [7"1, The domains A, B and C show homol- 
ogy with ¢-actinin, and A and B with spectrin as well. 
suggesting a cytoskeletal function for dystrophin [7]. 
consistent with its location. The A domain is thought 
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tO bind :Lctin, In the B domain of  human dystrophin 
four hinge segments were identified, which may play a 
role in the flexibility of dystrophin in the cytoskeleton 
[8]. Domains C and D are highly conserved between 
human and chicken, suggesting an important role for 
this region of dystrophin in the interaction with other 
cellular components [9]. The D domain is supposed to 
bc involved in the anchoring of dystrophin with gl~c- 
coprotcins in the plasmamembran¢ it0.11] and shows 
strong similarity with a dystrophin-like protein [12]. 
Five different eDNA fragments are selected for the 
construction of recombin:mt fusion proteins, Several 
antisera were raised using th¢~ fusion proteins as im- 
munog=ns. One polyclonal antibody named P20 is di- 
rected against the dystrophin part which corresponds 
with the deletion-prone P20 region of the DMD gone 
[13]. About half of the deletions found in the DMD/ 
BMD g=ne of Ducbenne and Becket patients are break- 
ing ila this so called P20 he/spot [14], The P20 AB has 
been characteri~d in detail and was found to be very 
specific and sensitive, and a valuable tool for dystrophin 
analysis. Similarly, the monoclonal antibody MAN- 
DRAI raised against he distal DRA poly~ptide [15], 
is now finding widespread use in the detection of distal 
dystrophin epitop=s [16-18]. 
2. MATERIALS AND METHODS 
~.. I, Pla,~mid c~m.~'tructi, m.r 
Human. fetal dystrophin eDNA clone~ w~re obtained from M, 
Kocnil~ [?], Nucleotid¢ and amino acid ~¢qucn¢c numbering are a~ in 
Kocnig et al. [7] and are depicted in Fill, I, 
Puhlis&,d by F./sevier Srit'nr¢ Puhlisht'rs B.V. 293 
Volume 308, number 3 
DMO cONA 
~mHt 





Pill Hu~lll TaRt 








a~g ~u mu ~lu 
I t I t  I 1 
P'20" TAQ* HD# DRA" 
Fig, I. Map of DMD eDNA re:;triction sites and number of dystrophin amino acids used for the construction of hybrid proteins, The pATH*. 
fusion proteins are d<noted with ' and the pEXI fusion proteins with #. The four domains, four hinges and intcrdomain segment arc according 
to Kocnig and Kunkcl [el and are indicated by A, B. C. D, hatched boxes and an arrow, respectively, 
2,2, Cmumwtim~ af fi~.~km pruleh~ ~tenex 
Two dilTcrcnt expression vectors pATH2 and i,EXI v.~:rc u,=~ to 
obtain the in.frame (DMD) gen¢ construct,:, Expr¢~ion of the con- 
structs in E. rob yielded fusion products containing different dystro. 
phin segments (Table [). 
2,2,1. Construction of fusion proteins using the pATH2 vector 
P20.pATH2 plasm/d construct 
A I.$ k b fragment of DM D eDNA(47-4) [7] obtained after digestion 
with Pst[(5456) and Hi,dll[(69.~3) was subcloncd into a partial (Pxtll 
t /hMIi l )  digest of a bacterial expression vector pATH2 [19]. which 
contains the first 969 nucleotid*.s of the trpE gent. The resulting 
recombinant vector fused 33 kDa of the trpE protein to 59 kDa of 
dystrophin (amino ,*rid sequence 1749--2248: Fig. I). yielding fusion 
protein P20 (Table |), 
T.~ Q.pA Tl/2 #ha'mid canxlrurl 
A 1.2 kb Taq[ (?1~75-9132) fragment of eDNA(63.1}, blunt.ended 
with DNA polymenm: l (Klenow fragmcntL ~,as inserted into the 
5"mat site of pATH2, The ¢on,=truct¢d fusion protein, named TAQ, 
contained 4ff kDa ol'dy~trophin (amino arid ~quen.-'-: 255"/.-297.~; Fig, 
1. T;~ble 1), 
D flA.p,! TH2 plosmid caR,f/rite/ 
A I,S kb DraI (9g05-11634) fragment ofcDNA(6,~.|) was in~rted 
into the Sinai site of pATH2. The obtained fusion protein, named 
DRA, includes the last 485 amino acid~ of dystrophin (amino acid 
sequence 3200-3685; Fig. l, Tatdc [). 
2.2,2. Construct{on of fusion proteins using tl~e pEXI vector 
BD-pEX[ construct 
DMD cDNA{X$10) wa,= digested with flumHl(4OTyDrnitl9?~) 
blunt-ended using DNA polymera~ I (Klenow) and inr~rtcd into the 
Sinai site of pEXI (Genofit Lid). an expression vc.:tor containing the 
lacZ gene [20], The resulting recombinant vector fused 101~ kDa of 
#-galactosidas¢ to 63 kDa of dystrophin (amino acid lequence 6"/- 
590), yielding fusion protein BD (Fig, 1, Table 1). HD.pEX[ construct, 
A 500 .Jlindlll(92tiiyDral(9805) fragment of cDNA(63-I ). blunt- 
ended by u~ing DNA polymerasc I (Klenow), was inserted =.to the 
Smal site of pEXI, The resulting fusion protein. HD, contain,= 21 kDa 
ofdystrophin (amino acid sequence 3026.-3199; Fig. I, Table I). 
2.3. txulution of fusion proteis~s and use ax h~ummogctts 
The recombinant plasmid pATH2 was introduced into E, cuff RRI 
cells, which were grown according to HolTman ¢t al. i l l ;  induction of 
the plasmic encoding protein espression, harvesting el' the ¢..¢11s and 
isolation o1" the fusion proteins were as described [14] except for the 
addition ofO.2S mM protea.e inhibitor PMSF during lysozyme trot* 
meat and ;t short son=cation to sllear the DNA =slier lysis oi" the c=ll~. 
The recombinant vectors pEXI were introduced into /2'... coil 
POP2136 cells, grown in NZY at 30"C to log phase and induced for 
90 rain at 37"C, harvested (10 rain at 500xX) and lyscd ,n STE (15~ 
• ucrorm; SO mM 'rris.HCI, pH St; S0 mM EDTA) with lysozynl¢ (J0 
mg/ml) containing Triton X-IO0 (0,2~,). The suspension containing 
the insoluble fusion proteins was ~nicmcd for I 5 s to whir  the DNA 
and centrifuged (12,000xg for IS rain at 4"C); the pellet was resus- 
p~nded in PBS and stored at -?0"C, Between $ and 10 mg of the 
different fusion proteins were isolated from 100 ml induced baclerial 
culture. The protein concent~tinns were determined (Bio.Rad protein 
assay), The I'usion proteins w~:rc used to immuni=: rabbits (New Zea. 
land White) accordinff to Harlow and Lane [21], Purification of the 
fusion proteins ~forc their use as -n antigen was not found to t-m a 
prerequisite, 
2.4. hmm.mhi~n~rhrmicul sminhJ~ 
Mul l= tissue was either fixed dir~:ctiy at room temperature over. 
night in metbanol/acctondacctic acid/water (.15:35:5:25, v/v/v/v) for 
lowed by dehydration and embedding in paraplast (Monojs:ct) [22] or 
fro~:n directly in isopcntan¢ chilled in liquid nitro~m and #,ored at 
-'/0"C until use, For immunohistochemical staining. 5 pro.thick sec. 
tions of muscle tissue were immunos'~ained asdcscril~d by Moorman 
• t al, [..33], The sera were diluted in PBS, 
2,5, Gel elerlru/shurexix aug IVextetu bh~llhl# 
Extortion and sampling of proteins from muscle biopsies were 
according to Hoffman et :d, [I] ex~pt that wc used 10x sampling 
buffer, Gel clectrophorcsis, protein transfer --nd antibody incubation 
were as described by Weasels et al. [24], Fusion proteins were electro. 
phoreti~ily rmpa~ted on SDS.polyaewlamide gels using a 4% ,=tack. 
ing gel and a %S% resolving el. To detem~ine the molecul,tr weights. 
presto=ned molecular weigM markers (Sigma) were urmd, To identify 
the a.actinin polypeptide a monoclonal antibody a~inst ~c-actinin 
(Sigma) was used. 
Table I 
In~:rt si~s DMD eDNA, dedu~d amino acid ~?..qucn~s :rod corr¢. 
sponding fusion protein s i~ 
Name Expression Size (kb) Amino acid Size (kDa) 
fusion vector insert sequence fusion 
protein (eDNA) protein 
BD pE.X I 1,6 68-590 169 
P20 pATH2 i .5 1749-224B 9 l 
TAQ pATH2 t .3 2SS'}-29"}5 gl 
H D pEX 1 0.5 3026-.3199 128 
DRA pATH2 1.4 3200-36115 8cJ 
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3, RESULTS AND DISCUSSION 
3,1, ~wJres~ion affusiota proteins 
in this study two different bacterial expression vector 
systems, pATH2 and pEXI, wcrc used (Table I), The 
positions of the resulting fusion proteins on the dystro. 
phin molecule are depicted in FiB, 1 and their analysis 
is shown in Fig. 2, The expression of pATH2 fusion 
proteins ,#as induced biochemicaliy: besides the pre- 
dominant bands in agreem~,nt with the expected siz.¢ of 
the fusion proteins, some background proteins of the 
bacterial host, E. cofi RRI andJor proteolytically de- 
g rad~ fusion proteins were copr~ipitated (Fig. 2: lanes 
3, 4 and 5), Coprecipitation "also occurred in another 
host strain, E. coli 1046 (not shown). Therefore, new 
constructs were made in the pEX expression system 
[20]. The pEX expression system makes use of a temper- 
ature-inducibl¢ promoter and shows predominantly the 
fusion protein bands (Fig. 2: lanes 7 and 8), in this 
expression system hardly any degradation product was 
pr~ent and/or the amount of bacterial proteins in the 
insoluble protein fraction was rather low, These results 
showy that the pEX expression system gives a higher 
yield of fusion protein compared with the pATH2 sys- 
tem. 
The insoluble fusion protein fractions obtained with 
both systems could be used dircctty as immunogcns in
rabbits, 
3.2. Characteri'-ation f the antibodies raised 
3,2,1, Polyclonal antisera, A number of very sensitive 
rabbit antiscra rc raised with the trpE fusion proteins: 
the 30 kDa axed 60 kDa untisera raised by Hoffman ¢t 
al. [1] and the P20 and TAQ antisera in our stud),. T~',,- 
P20 AB reacts both with native and denatured protein 
and can bc used at very high scram dilutions on sections 
(1:500.- 1000) as well as on Western blots (!: 1,000) (Figs, 
3 and 4). Using P20 AB. fixed scctions of normal mouse 
and human muscle tissue showed a clear staining of the 
sarcolemma (Fig. 3A} and in sections of  DMD muscle 
tissue no dystrophin was observed (Fig. 3B). On West- 
ern blots, P20 AB identified the 42? kDa dystrophin 
band besides a minor band of  95 kDa. This appears due 
to some a-actinin crossrcaction (Fig. 4: Lane 1). since the 
9S kDa band on blots was also recognized by a mono- 
clonal antibody against n.actinin (not shown}, while in 
the muscle extract of DMD patients the dystrophin 
baird was absent and the 95 kDa band present (Fig. 4: 
lane 2). This observation i dicates the sharing of anti- 
genie determinants between =-aetinin and this region of 
the dystrophin B domain. For diagnostic purposes the 
amount of ¢-actinin identified with P20 AB has turned 
out to be a valuable indicator for the amount ef muscle 
proteins present in the muscle extracls. 
The polyclonal antiseru BD and TAQ also identified 
a major dystrophin band next to a 95 kDa =-actinin 
band (no shown), In total 20 rabbits were immunized 
with the various fusion proteins. So far most successful 
immunizations were obtained using fusion proteins 
from the B domain: the 30 kDa and 60 kDa fusion 
proteins from Lloffman et al. [1] (not shown) and our 
P20 and TAQ fusion proteins (Fig, l}. 
3.2.2. Moncelonal antibodies. Fusion proteins con- 
taining the deletion prone area of the B domain and the 
D domain of dystrophin P20 and DRA. respectively 
(Fig. I), were also used to generate monoclonal antibod- 
ies [I 5,25]. Some P20 mono,:!on~l "-ntibodies identified 
1 2 3 4 5 6 7 8 9 
200 
9? ~ t 
• .~ ...... , ~ :  
43 liD" .~  .... ".... '-~:.- 
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O cmqw,g ; ,~ ,  , -  ' ' 
Fil~. 2. A ?..5% SDS.PAGE offiv¢ dilTclcnt fusion proteins. Lanes 3, 4 and • are loaded with trpE hybrid proteins: DRA, TAQ anti P20. respectively, 
Lane5 7 and 8 are loaded with pEXI fusion proteins, HD and BD, In lan~ I and 6 molecular weight markers arc shown and in the lanes { and 
9, trpE and ~-galactolidas¢. respectively. 
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FIll, 4, A W~tern blot of muscle xtracts separated on a 4-7~i, Ir~dicnt 
8cl SDS-PAGE attd incubated with P20 AB (h 1,0001, C: nomlal, adult 
n'tu~le ti=su¢; DMD, DMD tnuscl¢ tissue, 
P 
FiB. 3, Sections of human fixed muscle cells incub~t,~l with P20 AB 
(1:1.(100), A. normal human mu~cl=; B. DMD muscle, Ma~nifictttion= 
x325. 
both dystrophin and ¢z.acdnin. underscoring the homof 
ogy of their B domains [25]. 
Two cl-'tsse.~ of monoclonal a=~tibodies could b¢ dis- 
criminated using the fusion protein DRA as immurm- 
gen: one type binding exclusively to dystrophin and 
another type binding to a cross-reactin~ dystrophin-likc 
protein [15]. Besides the improvement of using mono. 
clonal .'*ntibodies tbr dystrophin analysis, this obs=rva. 
tion also shows the importance of using fusion proteins 
as immunoBens. Thus antibodies may be raised, which 
also identify dystrophin-like proteins. The dystrophin. 
exclusive antibody MANDRAI h~s ~in¢¢ found wide- 
spread use as a specific reagent for the COOH terminus 
of dystrophin [t6-18]. 
A panel of,~ensitive antis=ra gainst different parts of 
,:.lystrophin is of 13rent value for diasnostie purposes, 
Such a set of amibodi=s may phJpoint the localization 
of the mut.tion in the DMD gene [26], This is of special 
inte,'est in those DMD/BMD families (35%) for which 
DNA analynis does not currently show detectable ab- 
normalities of the DM D gene. In protein analysis, trun- 
cated dystrophins can be identified [26.2"/]. which may 
guide to further examination of the region of interest for 
small t'nutations leading to fi-ameshift ~nd/or early ter- 
mination of the DMD Rene [271, 
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